Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
(Date:9/18/2014)... 2014 Pipette.com announces brand new ... Capp, and AccuPet brand of pipettes. Micropipettes are ... or less and are a great tool for ... , The micropipette promotions were designed to offer ... products to help customers find the right solution. ...
(Date:9/17/2014)... -- The global consumption of squalene / squalane is expected ... skin-identical chemical that finds applications in various end user industries ... in other applications like high grade lubrication, and fiber coating ... players and is regionally segregated. Sophim ( France ... ( Japan ), SeaDragon Marine Oils Ltd. ( ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... 2 clinical trial using intravenous,administration of REOLYSIN(R) in ... head and neck cancers. The Principal,Investigator is Dr. ... Center,(CTRC) at The University of Texas Health Science ...
... Senior-friendly ,PlanPrescriber, Software Simplifies Medicare - For Free, ... today,announced the latest release of their PlanPrescriber tool. ... worry about whether they are,getting the most out ... MIT Professor Glen Urban, provides users with easy ...
... InNexus,Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF),( ... generation of monoclonal antibodies based on its Dynamic ... Chairman, to present,during the Wall Street Analyst Forum ... September 10, 2008., CEO and Chairman, Jeff ...
Cached Biology Technology:Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC 2
(Date:9/18/2014)... New research into the Crimean-Congo hemorrhagic fever virus (CCHFV), ... in humans similar to that caused by Ebolavirus, has ... discovery has the potential to lead to novel targets ... The research, reported in a paper published today in ... scientists at the Texas Biomedical Research Institute and their ...
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... June 17 bioMETRX, Inc. (OTC,Bulletin Board: BMRX) ... announced that the Handgun Club of America has ... showing great interest in,bioMETRX,s smartTOUCH(TM) bioVAULT 2.0 and ... the touch of a finger, and recognition,taking less ...
... related to analyses of the amphioxus ( Branchiostoma floridae ... a cephalochordate residing in shallow regions of tropical and ... lacking pairs of eyes, limbs, and ears. A ... squirts) and vertebrates, amphioxus lacks the backbone or spinal ...
... genome of a marine creature led by scientists at Scripps ... light on a key area of the tree of life. ... her colleagues from the United States, Europe and Asia, have ... a small, worm-like marine animal called amphioxus, also known ...
Cached Biology News:bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 3Genome sequence of small marine creature sheds light on vertebrate origins 2Genome sequence of small marine creature sheds light on vertebrate origins 3Worm-like marine animal providing 2Worm-like marine animal providing 3
...
...
...
... Clone/PAD: ZMD.366. Immunogen: ... internal region of human SENP1. ... human ~73 kDa SENP1. ... or DYKDDDDK)-HA-tagged-SENP1 transfected Hep2 cell ...
Biology Products: